KÔL reaches two new milestones in its commitment to rare eye diseases.
Orphan drug designation (ODD) in Europe for the prevention of corneal graft rejection marks a first major step forward and highlights the need for new approaches to better protect transplant patients.
This momentum continues with the enrolment of the first two patients in the PRECON study, conducted as part of the European Restore Vision initiative.
From regulatory recognition to clinical research, these advances reflect the same ambition: to drive innovation forward to meet the needs of patients with rare eye diseases.
Corneal neovascularisation: KÔL reaches two new milestones